ASP 5094

Drug Profile

ASP 5094

Alternative Names: ASP5094

Latest Information Update: 28 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astellas Pharma
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Integrin alpha9 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis

Most Recent Events

  • 28 Aug 2017 Astellas Pharma plans a phase II trial for Rheumatoid arthritis (Adjunctive treatment) (NCT03257852)
  • 31 Jul 2017 Phase-II clinical trials in Rheumatoid arthritis in Japan (IV) (Astellas pipeline, July 2017)
  • 11 Nov 2016 Safety and pharmacokinetics results from the phase I trial in Rheumatoid arthritis presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals (ACR-ARHP-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top